|
| International Business - FDFs (Finished Dosage Forms) :
|
|
|
|
(A)
Regulated
Markets
|
|
(B)
Emerging
Markets
|
|
(C)
Services
|
|
|
|
|
|
|
|
Regulated
Markets :
|
Indoco operates on CRAMS model (Contract Research And Manufacturing
Services) and currently caters to Generic Companies in Europe, USA,
Australia, New Zealand and South Africa.
While we have established our credentials by offering the contract
manufacturing services, Indoco has now risen in the value chain by
offering dossier development services and out-licensing of our own
dossiers.
Dosages Offered :
- Solid Dosages : The manufacturing facility with an
annual capacity of 3 billion tablets has been approved by UK-MHRA,
German Authorities, ANVISA – Brazil, MCC – South Africa & TGA
Australia.
- Creams & Ointments : The manufacturing facility has
been approved by UK-MHRA, MCC – South Africa & TGA Australia.
- Liquid Orals : The manufacturing facility has been
approved by UK-MHRA, MCC – South Africa & TGA Australia and
awaiting the inspection by UK-MHRA.
- Ophthalmics : The sterile facility for ophthalmic
solution has been approved by US-FDA and MCC – South Africa.
Having consolidated its presence in Regulated markets of Europe and
with an impressive entry in US markets, Indoco has also
strengthened its presence in the Emerging markets for
over a decade.
|
|
Top |
Click here to view product list
|
|
|
|
|
|
|
|
|
Emerging
Markets :
|
Currently, we export our products to countries like Algeria,
Azerbaijan, Bolivia, Ethiopia, Eritrea, Egypt, Ghana, Guatemala,
Haiti, Honduras, Jordan, Ivory Coast, Kenya, Liberia, Malaysia,
Mauritius, Macau, Moldova, Myanmar, Mozambique, Peru, Senegal, Sri
Lanka, Sierra Leone, Tanzania, Thailand, Trinidad & Tobago,
Ukraine, Uganda, Vietnam, Yemen and Zambia. Thus,
Indoco’s global stride in Emerging markets extends across
35 countries in four continents viz.
South East Asia, Africa, Latin America and CIS. We have 450 active product registrations and another 300 pending registrations.
We are consistently delivering high quality products at affodable prices and we are constantly upgrading our offerings into these markets.
The marketing efforts for the branded generics are highly focused
with country specific promotional inputs. The trained and motivated
Sales force is responsible to generate prescriptions and build
customer loyalty.
In addition, introduction of new products in existing markets and
entry in new territories will spur the growth in Emerging markets.
Products in new therapeutic segments are being targeted at existing
as well as new markets to further strengthen Indoco’s presence in
the Emerging markets
|
|
Top |
Click here to view product list
|
|
|
|
|
|
|
|
|
|
|
|
|
